Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 1
2003 2
2004 1
2005 1
2006 4
2007 2
2008 1
2010 2
2020 0
Text availability
Article attribute
Article type
Publication date

Search Results

14 results
Results by year
Filters applied: . Clear all
Page 1
Peptide-based vaccines in breast cancer.
Disis ML, Salazar LG, Knutson KL. Disis ML, et al. Breast Dis. 2004;20:3-11. doi: 10.3233/bd-2004-20102. Breast Dis. 2004. PMID: 15687702 Review.
Immunotherapy for breast cancer.
Knutson KL, Bishop MR, Schiffman K, Disis ML. Knutson KL, et al. Cancer Chemother Biol Response Modif. 2002;20:351-69. Cancer Chemother Biol Response Modif. 2002. PMID: 12703214 Review. No abstract available.
HLA-A2-restricted T-cell epitopes specific for prostatic acid phosphatase.
Olson BM, Frye TP, Johnson LE, Fong L, Knutson KL, Disis ML, McNeel DG. Olson BM, et al. Cancer Immunol Immunother. 2010 Jun;59(6):943-53. doi: 10.1007/s00262-010-0820-6. Epub 2010 Feb 6. Cancer Immunol Immunother. 2010. PMID: 20140431 Free PMC article.
His-tag ELISA for the detection of humoral tumor-specific immunity.
Goodell V, McNeel D, Disis ML. Goodell V, et al. BMC Immunol. 2008 May 29;9:23. doi: 10.1186/1471-2172-9-23. BMC Immunol. 2008. PMID: 18510754 Free PMC article.
Immunoediting of cancers may lead to epithelial to mesenchymal transition.
Knutson KL, Lu H, Stone B, Reiman JM, Behrens MD, Prosperi CM, Gad EA, Smorlesi A, Disis ML. Knutson KL, et al. J Immunol. 2006 Aug 1;177(3):1526-33. doi: 10.4049/jimmunol.177.3.1526. J Immunol. 2006. PMID: 16849459 Free article.
Treatment failure of a TLR-7 agonist occurs due to self-regulation of acute inflammation and can be overcome by IL-10 blockade.
Lu H, Wagner WM, Gad E, Yang Y, Duan H, Amon LM, Van Denend N, Larson ER, Chang A, Tufvesson H, Disis ML. Lu H, et al. J Immunol. 2010 May 1;184(9):5360-7. doi: 10.4049/jimmunol.0902997. Epub 2010 Mar 22. J Immunol. 2010. PMID: 20308630 Free article.
Future directions in the management of ovarian cancer.
Disis ML, Rivkin S. Disis ML, et al. Hematol Oncol Clin North Am. 2003 Aug;17(4):1075-85. doi: 10.1016/s0889-8588(03)00054-6. Hematol Oncol Clin North Am. 2003. PMID: 12959192 Review.
Sensitivity and specificity of tritiated thymidine incorporation and ELISPOT assays in identifying antigen specific T cell immune responses.
Goodell V, dela Rosa C, Slota M, MacLeod B, Disis ML. Goodell V, et al. BMC Immunol. 2007 Sep 12;8:21. doi: 10.1186/1471-2172-8-21. BMC Immunol. 2007. PMID: 17850666 Free PMC article.
The tumor antigen repertoire identified in tumor-bearing neu transgenic mice predicts human tumor antigens.
Lu H, Knutson KL, Gad E, Disis ML. Lu H, et al. Cancer Res. 2006 Oct 1;66(19):9754-61. doi: 10.1158/0008-5472.CAN-06-1083. Cancer Res. 2006. PMID: 17018635 Free article.
Antibody immunity to the p53 oncogenic protein is a prognostic indicator in ovarian cancer.
Goodell V, Salazar LG, Urban N, Drescher CW, Gray H, Swensen RE, McIntosh MW, Disis ML. Goodell V, et al. J Clin Oncol. 2006 Feb 10;24(5):762-8. doi: 10.1200/JCO.2005.03.2813. Epub 2006 Jan 3. J Clin Oncol. 2006. PMID: 16391298
14 results
You have reached the last page of results. A maximum of 10,000 results are available.
Jump to page